Ignite Creation Date:
2025-12-25 @ 12:58 AM
Ignite Modification Date:
2026-01-03 @ 4:50 PM
Study NCT ID:
NCT05241093
Status:
RECRUITING
Last Update Posted:
2025-04-10
First Post:
2022-01-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor:
Tarapeutics Science Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed or Refractory Acute Myeloid Leukemia (AML) | View |
Keywords: